A
Alcista
Alcista · 25%ABP
$0.24
Precio del escenario
$0.522
-0.181 (-34.76%)Al cierre
Loading chart…
- Máximo
- 0.780
- Apertura
- 0.759
- Precio medio ponderado por volumen
- 0.61
- Volumen
- 3.26M
- Capitalización
- —
- Mínimo
- 0.517
- Importe
- 1.98M
- EV/EBITDA, TTM
- 0.00
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Análisis de IA of ABPRO Holdings Inc (ABP)
VenderABPRO Holdings Inc (ABP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals to justify a buy decision.
Métricas de valoración
El PER previsto actual de ABPRO Holdings Inc (ABP) es -0.63, frente a su media de 5 años de -1.48.
Escenarios de precio de Alphio AI para ABP
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.502-12BenzingaFastly Reports Strong Quarterly Earnings Exceeding Expectations
4.502-10BenzingaU.S. Stocks Mixed in Morning Trading
9.502-10BenzingaCredo Technology Raises Revenue Guidance Significantly
9.012-15GlobenewswireAbpro Submits IND for ABP-102/CT-P72, Initiating Phase 1 Clinical Trial
9.012-15NewsfilterAbpro Submits IND Application for ABP-102/CT-P72, Targeting HER2-Positive Cancers
Preguntas frecuentes sobre ABP, respondidas por Alphio AI
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD). It operates in the Healthcare sector.
ABPRO Holdings Inc (ABP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals to justify a buy decision.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.